# GKS Presents Research Poster at BARDA BioMaP-Consortium General Membership Meeting 2026

Source: https://www.globalkeysolutions.net/media/gks-presents-research-poster-at-barda-biomap-consortium-general-membership-meeting-2026
Type: press_release
Published: February 25, 2026
Updated: March 12, 2026
Authors: KeyPedia Agent, Zephaniah Odidika

> Global Key Solutions presents FDA foreign inspection gap research at the 2026 BioMaP-Consortium General Membership Meeting hosted by BARDA/ASPR in Arlington, VA.

---

Global Key Solutions is presenting a research poster at the [BioMaP-Consortium General Membership Meeting](https://web.cvent.com/event/291448bb-e676-4375-8132-c20c4042d14f/websitePage:0b4e978b-6f1d-4e24-8599-e945a74d6f70) on February 25–26, 2026 in Arlington, VA. The event is organized by ATI in partnership with BARDA and ASPR, and focuses on strengthening domestic biopharmaceutical manufacturing capabilities.

## The Poster

Our poster, *"The Foreign Inspection Gap: Regulatory Data Intelligence for Global GMP Oversight,"* presents findings from our ongoing research on FDA foreign inspection trends from 2014–2024, along with an overview of the KeyPedia platform.

<iframe src="https://storage.googleapis.com/gks-blog-pdfs/blog-pdfs/45ee1c75bffd42baa07989ba1e6eecb3.pdf" width="100%" height="600" style="border: none; border-radius: 6px; box-shadow: 0 2px 8px rgba(0,0,0,0.1); margin: 1.5rem 0;">
  <p>PDF preview not available. <a href="https://storage.googleapis.com/gks-blog-pdfs/blog-pdfs/45ee1c75bffd42baa07989ba1e6eecb3.pdf" target="_blank">View Poster PDF</a></p>
</iframe>

### Key Findings

- **23 fewer inspections** for every additional $1 billion of drug imports (2014–2019)
- **China inspection intensity down 82%** (101.8 → 18.3 per billion USD)
- Foreign facilities showed observation rates **1.3–1.8x higher** than the U.S. baseline (49.3%)

These findings provide empirical support for the FDA's May 6, 2025 policy shift toward unannounced foreign facility inspections.

## The Event

GKS is one of 14 organizations selected to present posters at the meeting, alongside KBI Biopharma, General Therapeutics, Arranta Bio, and others. The two-day agenda features keynotes from ASPR and BARDA leadership, panels on onshoring pharmaceutical manufacturing, and sessions on supply chain resilience.

<iframe src="https://storage.googleapis.com/gks-blog-pdfs/blog-pdfs/c53c67bc086d449aa848032118ba1904.pdf" width="100%" height="600" style="border: none; border-radius: 6px; box-shadow: 0 2px 8px rgba(0,0,0,0.1); margin: 1.5rem 0;">
  <p>PDF preview not available. <a href="https://storage.googleapis.com/gks-blog-pdfs/blog-pdfs/c53c67bc086d449aa848032118ba1904.pdf" target="_blank">View Digital Agenda</a></p>
</iframe>

## Related Research

- **Preprint:** [The Foreign Inspection Gap: FDA GMP Oversight of U.S. Drug Imports, 2014–2024](https://doi.org/10.21203/rs.3.rs-7849765/v1) — Research Square, 2025
- **Published:** [An Analysis of FDA Warning Letter Citations from 2019–2023](https://doi.org/10.1007/s12247-024-09879-x) — *J. Pharm. Innov.* 19, 78 (2024)

![Screenshot 2026-02-24 at 8.07.52 PM.png](https://storage.googleapis.com/gks-blog-images/blog-images/139ae00525314c0f9219014e45e10123.png)



---

For more information, questions, or to see KeyPedia in action, [try KeyPedia Light](https://www.globalkeysolutions.net/browse) or [schedule a demo](https://www.globalkeysolutions.net/auth/signin). You can also reach us at [hello@globalkeysolutions.net](mailto:hello@globalkeysolutions.net).